nach oben

Erschienen in:

04.11.2016 | Meta-Analysis

The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke

verfasst von: Sina Jasim, Fares Alahdab, Ahmed T. Ahmed, Shrikant U. Tamhane, Anu Sharma, Diane Donegan, Todd B. Nippoldt, M. Hassan Murad

Erschienen in: Endocrine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Growth hormone replacement therapy has benefits for patients with hypopituitarism. The safety profile in regard to tumor recurrence or progression, development of secondary malignancies, or cerebrovascular stroke is still an area of debate. A comprehensive search of multiple databases—MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus was conducted through August 2015. Eligible studies that evaluated long-term adverse events in adult patients with hypopituitarism treated with growth hormone replacement therapy and reported development of pituitary tumor recurrence or progression, secondary malignancies, or cerebrovascular stroke were selected following a predefined protocol. Reviewers, independently and in duplicate, extracted data and assessed the risk of bias. Random-effects meta-analysis was used to pool relative risks and 95 % confidence intervals. We included 15 studies (published 1995–2015) that reported on 46,148 patients. Compared to non-replacement, growth hormone replacement therapy in adults with hypopituitarism was not associated with statistically significant change in pituitary tumor progression or recurrence (relative risk, 0.77; 95 % confidence interval, 0.53–1.13) or development of secondary malignancy (relative risk, 0.99; 95 % confidence interval, 0.70–1.39). In two retrospective studies, there was higher risk of stroke in patients who did not receive replacement (relative risk, 2.07; 95 % confidence interval, 1.51–2.83). The quality of evidence is low due to study limitations and imprecision. This systematic review and meta-analysis supports the overall safety of growth hormone therapeutic use in adults with hypopituitarism with no clear evidence of increased risk of pituitary tumor recurrence, malignancy, or stroke.

A.A. Toogood, C.G. Beardwell, S.M. Shalet, The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin. Endocrinol. 41(4), 511–516 (1994)CrossRef

K. Stochholm, C.H. Gravholt, T. Laursen, J.O. Jorgensen, P. Laurberg, M. Andersen, L.O. Kristensen, U. Feldt-Rasmussen, J.S. Christiansen, M. Frydenberg, A. Green, Incidence of GH deficiency—a nationwide study. Eur. J. Endocrinol. 155(1), 61–71 (2006). doi:10.1530/eje.1.02191 CrossRefPubMed

A. Agha, M. Sherlock, S. Brennan, S.A. O’Connor, E. O’Sullivan, B. Rogers, C. Faul, D. Rawluk, W. Tormey, C.J. Thompson, Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J. Clin. Endocrinol. Metab. 90(12), 6355–6360 (2005). doi:10.1210/jc.2005-1525 CrossRefPubMed

M.D. Littley, S.M. Shalet, C.G. Beardwell, S.R. Ahmed, G. Applegate, M.L. Sutton, Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quat. J. Med. 70(262), 145–160 (1989)

L. Lonn, H. Kvist, U. Grangard, B.A. Bengtsson, L. Sjostrom, CT-determined body composition changes with recombinant human growth hormone treatment to adults with growth hormone deficiency. Basic. Life. Sci. 60, 229–231 (1993)PubMed

R. Abs, U. Feldt-Rasmussen, A.F. Mattsson, J.P. Monson, B.A. Bengtsson, M.I. Goth, P. Wilton, M. Koltowska-Haggstrom, Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur. J. Endocrinol. 155(1), 79–90 (2006). doi:10.1530/eje.1.02179 CrossRefPubMed

R.J. Irving, M.N. Carson, D.J. Webb, B.R. Walker, Peripheral vascular structure and function in men with contrasting GH levels. J. Clin. Endocrinol. Metab. 87(7), 3309–3314 (2002). doi:10.1210/jcem.87.7.8655 CrossRefPubMed

V. Markussis, S.A. Beshyah, C. Fisher, K.H. Parker, A.N. Nicolaides, D.G. Johnston, Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur. J. Endocrinol. 136(2), 157–164 (1997)CrossRef

J.O. Johansson, K. Landin, G. Johannsson, L. Tengborn, B.A. Bengtsson, Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. 76(3), 422–428 (1996)PubMed

10.

J. Kvasnicka, J. Marek, T. Kvasnicka, V. Weiss, M. Markova, J. Stepan, A. Umlaufova, Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin. Endocrinol. 52(5), 543–548 (2000). doi:10.1046/j.1365-2265.2000.01002.x CrossRef

11.

J.C. Carel, E. Ecosse, F. Landier, D. Meguellati-Hakkas, F. Kaguelidou, G. Rey, J. Coste, Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J. Clin. Endocrinol. Metab. 97(2), 416–425 (2012). doi:10.1210/jc.2011-1995jc.2011-1995 CrossRefPubMed

12.

R.C. Gaillard, A.F. Mattsson, A.C. Akerblad, B.A. Bengtsson, J. Cara, U. Feldt-Rasmussen, M. Koltowska-Haggstrom, J.P. Monson, B. Saller, P. Wilton, R. Abs, Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur. J. Endocrinol. 166(6), 1069–1077 (2012). doi:10.1530/EJE-11-1028EJE-11-1028 CrossRefPubMed

13.

J. Svensson, B.A. Bengtsson, T. Rosen, A. Oden, G. Johannsson, Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 89(7), 3306–3312 (2004). doi:10.1210/jc.2003-03160189/7/3306 CrossRefPubMed

14.

M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer. 4(7), 505–518 (2004). doi:10.1038/nrc1387nrc1387 CrossRefPubMed

15.

A. Wolk, C.S. Mantzoros, S.O. Andersson, R. Bergstrom, L.B. Signorello, P. Lagiou, H.O. Adami, D. Trichopoulos, Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer. Inst. 90(12), 911–915 (1998)CrossRef

16.

H. Yu, M.R. Spitz, J. Mistry, J. Gu, W.K. Hong, X. Wu, Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer. Inst. 91(2), 151–156 (1999)CrossRef

17.

S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B. Rosner, F.E. Speizer, M. Pollak, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351(9113), 1393–1396 (1998). doi:10.1016/S0140-6736(97)10384-1 CrossRefPubMed

18.

B. Delhougne, C. Deneux, R. Abs, P. Chanson, H. Fierens, P. Laurent-Puig, I. Duysburgh, A. Stevenaert, A. Tabarin, J. Delwaide, G. Schaison, J. Belaiche, A. Beckers, The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J. Clin. Endocrinol. Metab. 80(11), 3223–3226 (1995). doi:10.1210/jcem.80.11.7593429 CrossRefPubMed

19.

A.G. Renehan, S.,T. O’Dwyer, S.M. Shalet, Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. Gut. 46(3), 440–441 (2000)CrossRef

20.

J.E. Brunner, C.C. Johnson, S. Zafar, E.L. Peterson, J.F. Brunner, R.C. Mellinger, Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin. Endocrinol. 32(1), 65–71 (1990)CrossRef

21.

S. Ezzat, C. Strom, S. Melmed, Colon polyps in acromegaly. Ann. Intern. Med. 114(9), 754–755 (1991)CrossRef

22.

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 339, b2535 (2009). doi:10.1136/bmj.b2535bmj.b2535 CrossRefPubMedPubMedCentral

23.

R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials. 7(3), 177–188 (1986)CrossRef

24.

J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539–1558 (2002). doi:10.1002/sim.1186 CrossRefPubMed

25.

B.C. Wallace, I.J. Dahabreh., T.A. Trikalinos, J. Lau, P. Trow, C.H. Schmid, Closing the gap between methodologists and end-users: R as a computational back-end. J. Stat. Softw. 49(i05) (2012)

26.

M.H. Murad, V.M. Montori, J.P. Ioannidis, R. Jaeschke, P.J. Devereaux, K. Prasad, I. Neumann, A. Carrasco-Labra, T. Agoritsas, R. Hatala, M.O. Meade, P. Wyer, D.J. Cook, G. Guyatt, How to read a systematic review and meta-analysis and apply the results to patient care: users’ guides to the medical literature. JAMA. 312(2), 171–179 (2014). doi:10.1001/jama.2014.55591886196 CrossRefPubMed

27.

B.A. Swiglo, M.H. Murad, H.J. Schunemann, R. Kunz, R.A. Vigersky, G.H. Guyatt, V.M. Montori, A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93(3), 666–673 (2008). doi:10.1210/jc.2007-1907 CrossRefPubMed

28.

C.C. van Bunderen, I.C. van Nieuwpoort, L.I. Arwert, M.W. Heymans, A.A. Franken, H.P. Koppeschaar, A.J. van der Lely, M.L. Drent, Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the dutch national registry of growth hormone treatment in adults. J. Clin. Endocrinol. Metab. 96(10), 3151–3159 (2011). doi:10.1210/jc.2011-1215jc.2011-1215 CrossRefPubMed

29.

A.J. Swerdlow, R.E. Reddingius, C.D. Higgins, H.A. Spoudeas, K. Phipps, Z. Qiao, W.D. Ryder, M. Brada, R.D. Hayward, C.G. Brook, P.C. Hindmarsh, S.M. Shalet, Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J. Clin. Endocrinol. Metab. 85(12), 4444–4449 (2000). doi:10.1210/jcem.85.12.7044 CrossRefPubMed

30.

G. Frajese, W.M. Drake, R.A. Loureiro, J. Evanson, D. Coyte, D.F. Wood, A.B. Grossman, G.M. Besser, J.P. Monson, Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J. Clin. Endocrinol. Metab. 86(11), 5172–5175 (2001). doi:10.1210/jcem.86.11.8018 CrossRefPubMed

31.

N.C. van Varsseveld, C.C. van Bunderen, A.A. Franken, H.P. Koppeschaar, A.J. van der Lely, M.L. Drent, Tumor recurrence or regrowth in adults with nonfunctioning pituitary adenomas using GH replacement therapy. J. Clin. Endocrinol. Metab. 100(8), 3132–3139 (2015). doi:10.1210/jc.2015-1764 CrossRefPubMed

32.

P. Maison, S. Griffin, M. Nicoue-Beglah, N. Haddad, B. Balkau, P. Chanson, Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 89(5), 2192–2199 (2004). doi:10.1210/jc.2003-030840 CrossRefPubMed

33.

M. Bex, R. Abs, D. Maiter, A. Beckers, G. Lamberigts, R. Bouillon, The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J. Bone. Miner. Res. 17(6), 1081–1094 (2002). doi:10.1359/jbmr.2002.17.6.1081 CrossRefPubMed

34.

M. Koltowska-Haggstrom, A.F. Mattsson, J.P. Monson, P. Kind, X. Badia, F.F. Casanueva, J. Busschbach, H.P. Koppeschaar, G. Johannsson, Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur. J. Endocrinol. 155(1), 109–119 (2006). doi:10.1530/eje.1.02176 CrossRefPubMed

35.

J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 357(9254), 425–431 (2001). doi:10.1016/s0140-6736(00)04006-x CrossRef

36.

T. Rosen, B.A. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336(8710), 285–288 (1990). doi:10.1016/0140-6736(90)91812-O CrossRefPubMed

37.

S.M. Haffner, M.P. Stern, H.P. Hazuda, M. Rosenthal, J.A. Knapp, R.M. Malina, Role of obesity and fat distribution in non-insulin-dependent diabetes mellitus in Mexican Americans and non-Hispanic whites. Diabetes. Care. 9(2), 153–161 (1986)CrossRef

38.

A.H. Kissebah, N. Vydelingum, R. Murray, D.J. Evans, A.J. Hartz, R.K. Kalkhoff, P.W. Adams, Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 54(2), 254–260 (1982). doi:10.1210/jcem-54-2-254 CrossRefPubMed

39.

M. Leonsson, J. Hulthe, J. Oscarsson, G. Johannsson, I. Wendelhag, J. Wikstrand, B.A. Bengtsson, Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin. Endocrinol. 57(6), 751–759 (2002). doi:10.1046/j.1365-2265.2002.01663.x CrossRef

40.

M. Pfeifer, R. Verhovec, B. Zizek, J. Prezelj, P. Poredos, R.N. Clayton, Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84(2), 453–457 (1999). doi:10.1210/jcem.84.2.5456 CrossRefPubMed

41.

R.W. McCallum, J.R. Petrie, A.F. Dominiczak, J.M. Connell, Growth hormone deficiency and vascular risk. Clin. Endocrinol. 57(1), 11–24 (2002). doi:10.1111/j.1365-2265.2005.02245.x CrossRef

42.

J.K. Devin, L.S. Blevins Jr., D.K. Verity, Q. Chen, J.R. Bloodworth Jr., J. Covington, D.E. Vaughan, Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 92(9), 3633–3639 (2007). doi:10.1210/jc.2007-0609 CrossRefPubMed

43.

S. Wakai, T. Fukushima, T. Furihata, K. Sano, Association of cerebral aneurysm with pituitary adenoma. Surg. Neurol. 12(6), 503–507 (1979)PubMed

44.

G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva, C. di Somma, G. Lombardi, A. Colao, Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab 87(7), 3174–3179 (2002). doi:10.1210/jcem.87.7.8643 CrossRefPubMed

45.

A. Poidvin, E. Touze, E. Ecosse, F. Landier, Y. Bejot, M. Giroud, P.M. Rothwell, J.C. Carel, J. Coste, Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. 83(9), 780–786 (2014). doi:10.1212/WNL.0000000000000737WNL.0000000000000737 CrossRefPubMed

46.

V. Popovic, A.F. Mattsson, R.C. Gaillard, P. Wilton, M. Koltowska-Haggstrom, M.B. Ranke, Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer international metabolic database). J. Clin. Endocrinol. Metab. 95(9), 4449–4454 (2010). doi:10.1210/jc.2010-0287jc.2010-0287 CrossRefPubMed

47.

J.M. Chan, M.J. Stampfer, E. Giovannucci, P.H. Gann, J. Ma, P. Wilkinson, C.H. Hennekens, M. Pollak, Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Sci. 279(5350), 563–566 (1998)CrossRef

48.

J. Ma, M. Pollak, E. Giovannucci, J.M. Chan, Y. Tao, C. Hennekens, M.J. Stampfer, A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth. Horm. IGF. Res. 10(Suppl A), S28–29 (2000)CrossRef

49.

T.J. Key, P.N. Appleby, G.K. Reeves, A.W. Roddam, Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet. Oncol. 11(6), 530–542 (2010). doi:10.1016/S1470-2045(10)70095-4S1470-2045(10)70095-4 CrossRefPubMed

50.

E. Seccareccia, P. Brodt, The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth. Horm. IGF. Res. 22(6), 193–199 (2012). doi:10.1016/j.ghir.2012.09.003S1096-6374(12)00085-8 CrossRefPubMed

51.

C.A. Sklar, A.C. Mertens, P. Mitby, G. Occhiogrosso, J. Qin, G. Heller, Y. Yasui, L.L. Robison, Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 87(7), 3136–3141 (2002). doi:10.1210/jcem.87.7.8606 CrossRefPubMed

52.

B. Ergun-Longmire, A.C. Mertens, P. Mitby, J. Qin, G. Heller, W. Shi, Y. Yasui, L.L. Robison, C.A. Sklar, Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol. Metab. 91(9), 3494–3498 (2006). doi:10.1210/jc.2006-0656 CrossRefPubMed

53.

B.C. Patterson, Y. Chen, C.A. Sklar, J. Neglia, Y. Yasui, A. Mertens, G.T. Armstrong, A. Meadows, M. Stovall, L.L. Robison, L.R. Meacham, Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J. Clin. Endocrinol. Metab. 99(6), 2030–2037 (2014). doi:10.1210/jc.2013-4159 CrossRefPubMedPubMedCentral

54.

C.J. Child, D. Conroy, A.G. Zimmermann, W.W. Woodmansee, E.M. Erfurth, L.L. Robison, Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the hypopituitary control and complications study. Eur. J. Endocrinol. 172(6), 779–790 (2015). doi:10.1530/EJE-14-1123EJE-14-1123 CrossRefPubMed

55.

T.T. Chung, W.M. Drake, J. Evanson, D. Walker, P.N. Plowman, S.L. Chew, A.B. Grossman, G.M. Besser, J.P. Monson, Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin. Endocrinol. 63(3), 274–279 (2005). doi:10.1111/j.1365-2265.2005.02338.x CrossRef

56.

A. Jostel, A. Mukherjee, P.A. Hulse, S.M. Shalet, Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin. Endocrinol. 62(6), 698–705 (2005). doi:10.1111/j.1365-2265.2005.02282.x CrossRef

57.

J.R. Arnold, D.F. Arnold, A. Marland, N. Karavitaki, J.A. Wass, GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin. Endocrinol. 70(3), 435–438 (2009). doi:10.1111/j.1365-2265.2008.03391.xCEN3391 CrossRef

58.

N.J. Gittoes, A.S. Bates, W. Tse, B. Bullivant, M.C. Sheppard, R.N. Clayton, P.M. Stewart, Radiotherapy for non-function pituitary tumours. Clin. Endocrinol. 48(3), 331–337 (1998)CrossRef

59.

M. Buchfelder, P.H. Kann, C. Wuster, U. Tuschy, B. Saller, G. Brabant, A. Kleindienst, P. Nomikos, Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur. J. Endocrinol. 157(2), 149–156 (2007). doi:10.1530/EJE-07-0164 CrossRefPubMed

60.

A.G. Hatrick, P. Boghalo, J.B. Bingham, A.B. Ayres, P.H. Sonksen, D.L. Russell-Jones, Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur. J. Endocrinol. 146(6), 807–811 (2002). doi:10.1530/eje.0.1460807 CrossRefPubMed

61.

D.S. Olsson, M. Buchfelder, K. Wiendieck, N. Kremenevskaja, B.A. Bengtsson, K.E. Jakobsson, M. Jarfelt, G. Johannsson, A.G. Nilsson, Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur. J. Endocrinol. 166(6), 1061–1068 (2012). doi:10.1530/EJE-12-0077EJE-12-0077 CrossRefPubMed

62.

K. Stochholm, G. Johannsson, Reviewing the safety of GH replacement therapy in adults. Growth. Horm. IGF. Res. 25(4), 149–157 (2015). doi:10.1016/j.ghir.2015.06.006 CrossRefPubMed

63.

C.C. van Bunderen, N.C. van Varsseveld, E.M. Erfurth, J.C. Ket, M.L. Drent, Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin. Endocrinol. 81(1), 1–14 (2014). doi:10.1111/cen.12477 CrossRef

64.

S. Mackenzie, T. Craven, H.R. Gattamaneni, R. Swindell, S.M. Shalet, G. Brabant, Long-term safety of growth hormone replacement after CNS irradiation. J. Clin. Endocrinol. Metab. 96(9), 2756–2761 (2011). doi:10.1210/jc.2011-0112 CrossRefPubMed

65.

D.S. Olsson, M. Buchfelder, S. Schlaffer, B.A. Bengtsson, K.E. Jakobsson, G. Johannsson, A.G. Nilsson, Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur. J. Endocrinol. 161(5), 663–669 (2009). doi:10.1530/EJE-09-0572 CrossRefPubMed

66.

H. Holmer, J. Svensson, L. Rylander, G. Johannsson, T. Rosen, B.A. Bengtsson, M. Thoren, C. Hoybye, M. Degerblad, M. Bramnert, E. Hagg, B. Eden Engstrom, B. Ekman, B. Norrving, L. Hagmar, E.M. Erfurth, Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. J. Clin. Endocrinol. Metab. 92(9), 3560–3567 (2007). doi:10.1210/jc.2007-0458 CrossRefPubMed

67.

A.J. Swerdlow, C.D. Higgins, P. Adlard, M.A. Preece, Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 360(9329), 273–277 (2002)CrossRef

68.

G. Mardh, A. Lindeberg, Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined clinical safety data from clinical trials in 665 patients. Endocrinol. Metab. 2(Suppl B), 11–16 (1995)

Titel: The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke
verfasst von: Sina Jasim
Fares Alahdab
Ahmed T. Ahmed
Shrikant U. Tamhane
Anu Sharma
Diane Donegan
Todd B. Nippoldt
M. Hassan Murad
Publikationsdatum: 04.11.2016
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-1156-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Interference in ACTH immunoassay negatively impacts the management of subclinical hypercortisolism

8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth

Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors

Optimal vitamin D supplementation strategies

High dose of radioactive iodine per se has no effect on glucose metabolism in thyroidectomized rats

Effect of cilostazol in treating diabetes-associated microvascular complications

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin